Looks like you’re on the UK site. Choose another location to see content specific to your location
Pfizer names new member of board of directors
Pfizer has announced the appointment of Ronald Blaylock as the newest member of its board of directors.
Mr Blaylock is the founder and managing partner of GenNx360 Capital Partners, a private equity firm. Prior to establishing the firm, he founded and managed an investment banking firm called Blaylock and Company.
He has also held senior management positions at UBS, PaineWebber Group and Citicorp, and can offer considerable experience of working in a variety of business leadership roles.
Mr Blaylock's appointment to the Pfizer board has also seen him selected as a member of the company's corporate governance and science and technology committees.
Ian Read, Pfizer's chairman and chief executive officer, said: "We are pleased to welcome Ron Blaylock to Pfizer's board of directors. He brings business, financial and leadership expertise, which will be an asset to Pfizer's diverse board and to our company."
Over the course of his career, the new board member has received a number of prestigious accolades, including being named capital raiser of the year by Corporate Finance Magazine and man of the year by Covenant House.
With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.
We have hundreds of jobs available across the Healthcare industry, find your perfect one now.
Stay informed
Receive the latest industry news, Tips
and straight to your inbox.
- Share Article
- Share on Twitter
- Share on Facebook
- Share on LinkedIn
- Copy link Copied to clipboard